搜索
Verrica Pharmaceuticals Inc
VRCA添加自选
6.270USD
-0.680-9.78%
收盘 05/15, 16:00（美东）报价延迟15分钟
107.71M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-9.78%
5天
-21.53%
1月
+0.97%
6月
+59.54%
今年开始到现在
-24.55%
1年
-5.33%
TradingKey Verrica Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Verrica Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名85/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.50。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Verrica Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Verrica Pharmaceuticals Inc亮点
亮点风险
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
业绩高增长
公司营业收入稳步增长，连续3年增长594.32%
业绩增长期
公司处于发展阶段，最新年度总收入35.58M美元
估值低估
公司最新PE估值-5.67，处于3年历史低位
机构加仓
最新机构持股5.43M股，环比增加18.99%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值26.40K
分析师目标
根据
5
位分析师
买入
评级
16.500
目标均价
+137.41%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Verrica Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Verrica Pharmaceuticals Inc简介
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
公司代码VRCA
公司Verrica Pharmaceuticals Inc
CEORieger (Jayson)
网址https://verrica.com/
相关品种
